文献速递前列腺癌

前部优势前列腺癌的临床病理特征与结局:对诊断和治疗的启示

Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-01-03

单机构匹配病例对照分析显示,前部优势前列腺癌(APCA)占根治性前列腺切除术患者的9.5%(150/1580)。与后部优势前列腺癌(PPCA)匹配后,APCA诊断时中位PSA更高(6.4 vs 5.6 ng/mL,p=0.04)、GrdGrp 1比例更高(57.7% vs 40.0%,p=0.003)、DRE异常率更低(10.1% vs 23.2%,p=0.003),手术升级率更高(55.3% vs 42.0%,p=0.015);5年生化失败无差异(p=0.70)。

要点

  • APCA多数DRE不可触及,诊断时PSA更高,易被漏诊。
  • APCA诊断时低/中级别比例高,但手术升级率超半数。
  • 匹配后APCA与PPCA的5年生化失败率无差异。

核心结论

  • APCA多DRE不可触及且诊断时PSA更高,虽多表现为低/中级别但手术升级常见。
  • 匹配后APCA与PPCA根治术后生化失败率无差异。

研究设计与样本

  • 单机构匹配病例对照分析,分析根治性前列腺切除术后的短期临床结局。
  • 2005至2013年共1580例患者,其中150例(9.5%)为APCA。

主要发现

  • APCA诊断时中位PSA为6.4(4.6-9.1)ng/mL,PPCA为5.6(4.4-8.1)ng/mL(p=0.04)。
  • APCA诊断时GrdGrp 1比例为57.7%,PPCA为40.0%(p=0.003)。
  • APCA DRE异常率为10.1%,PPCA为23.2%(p=0.003)。
  • APCA手术升级率为55.3%,PPCA为42.0%(p=0.015)。
  • APCA 5年生化失败自由率为85.1%(95%CI 73.1-98.9),PPCA为82.9%(95%CI 69.2-99.5)(p=0.70,log-rank检验)。

临床怎么用

  • 对DRE阴性但PSA升高者应警惕前部优势前列腺癌可能。
  • APCA诊断低/中级别时需考虑手术升级风险,制定手术方案应充分评估。

局限性

  • 单机构回顾性匹配分析,样本量有限。
  • 仅分析短期临床结局,缺乏长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to describe the pathological features and clinical outcomes in anterior-dominant prostate cancer (APCA) compared to posterior/posterolateral-dominant prostate cancer (PPCA) among men treated with radical prostatectomy for localized prostate cancer. METHODS: This is a single-institution, matched case-control analysis of short-term clinical outcomes stratified by pathologic tumor location at radical prostatectomy. Pathologic data extracted by expert genitourinary pathologists on tumor location was linked to clinical and oncologic outcomes data from a prospective institutional database for analysis. RESULTS: From 2005 to 2013, 1580 patients were identified for analysis with 150 (9.5%) having APCA. One-hundred and thirty two of these APCA men had complete clinical data and were matched to 353 men with PPCA (~1:3 ratio) by GrdGrp at surgery, margin status, and pathologic T stage. There were no racial/ethnic differences between APCA and PPCA (p = 0.13). Men with APCA demonstrated a higher median PSA at diagnosis (6.4 [4.6-9.1] ng/mL vs 5.6 [4.4-8.1] ng/mL; p = 0.04), a higher rate of GrdGrp 1 disease at diagnosis (57.7% vs. 40.0%, p = 0.003), and lower rates of abnormal digital rectal examination (DRE) (10.1% vs. 23.2%, p = 0.003) when compared to PPCA. The rate of surgical upgrading was higher among men with APCA vs. PPCA (55.3% vs 42.0%, p = 0.015). Freedom from biochemical failure (BF) at 5-years was 85.1% (95% CI 73.1-98.9) for APCA and 82.9% (95% CI 69.2-99.5) for men with PPCA (p = 0.70, log-rank test). CONCLUSIONS: The majority of anterior tumors were undetectable by DRE and were associated with higher PSA at diagnosis. Despite presenting mostly as low/intermediate grade cancers, more than half of the men with APCA had upgrading at surgery and slightly more than 40% had positive margins and/or extraprostatic disease. When matched to a cohort of posterior predominant tumors, no differences were seen in the rate of biochemical-failure after prostatectomy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Falzarano SM, Nyame YA, McKenney JK, et al. Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment. Prostate Cancer Prostatic Dis. 2020. PMID: 31900431. doi:10.1038/s41391-019-0199-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。